Lugsomya, Kittitat; Chatsuwan, Thanitta; Niyomtham, Waree; Tummaruk, Padet; Hampson, David J.; Prapasarakul, Nuvee (Thailand)
Microbial Drug Resistance (2018)
Samples were collected from 25 farms located across five Provinces of Thailand. The farms were selected based on their antimicrobial usage patterns. Twelve farms routinely used PAs; two only used antimicrobials therapeutically, TAs; and 11 small farms had never used antimicrobials, NAs. For the 12 PA farms, a routine in-feed antimicrobial use program had been followed for at least 2 years for endemic bacterial disease prophylaxis. A total of 102 fecal samples from individual 18- to 20- week-old fattening pigs with a normal appearance and no recent history of enteric or respiratory disease, or TA treatment, were obtained from the farms (7–10 samples per farm).A total of 70 fecal samples were obtained from similar fattening pigs on two TA farms that did not use PAs and only used the injectable antimicrobial enrofloxacin or gentamicin under veterinary prescription for individual treatment of specific clinical cases where the sick pigs were kept in isolation. Another 67 samples were collected from fattening pigs on the 11 NA farms, where there was no access to or use of antimicrobials or vaccination.
For each pig, at least 5 g of rectal feces was collected directly into a sterile container and delivered to the laboratory at 4C.
AST Method: None
Reference explicitly reports AST breakpoints: False
Reference reports using a MIC table: False
Is Excluded: False
Country | Sub-Region | Sub-Region Detail |
---|---|---|
Thailand | Other (Other) | Across 5 provinces |
ID | Note | Resolution |
---|
Title | Host | Host | Production Stage | Description | ROs |
---|---|---|---|---|---|
Prophylactic ampicillin use | Swine | Grower-finisher | Farm | Ampicillin use broken up by treatment group | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is blaTEM gene | 1 |
Therapeutic tiamulin use | Swine | Grower-finisher | Farm | Tiamulin use broken up by treatment group | 1 |
Therapeutic amikacin use | Swine | Grower-finisher | Farm | Amikacin use broken up by treatment group | 1 |
Therapeutic chloramphenicol use | Swine | Grower-finisher | Farm | Chloramphenicol use broken up by treatment group | 1 |
Prophylactic imipenem use | Swine | Grower-finisher | Farm | Imipenem use broken up by treatment group | 1 |
Therpeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is blaTEM gene | 1 |
Prophylactic tobramycin use | Swine | Grower-finisher | Farm | Tobramycin use broken up by treatment group | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is catA gene | 1 |
Therpeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is blaCTX-M9 gene | 1 |
Therapeutic piperacillin use | Swine | Grower-finisher | Farm | Piperacillin use broken up by treatment group | 1 |
Prophylactic marbofloxacin use | Swine | Grower-finisher | Farm | Marbofloxacin use broken up by treatment group | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is sul3 gene | 1 |
Prophylactic cefpodoxime use | Swine | Grower-finisher | Farm | Cefpodoxime use broken up by treatment group | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is dfrA12 gene | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is aadA2 gene | 1 |
Therapeutic ampicillin use | Swine | Grower-finisher | Farm | Ampicillin use broken up by treatment group | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is dfrA12 gene | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is aadB gene | 1 |
Therapeutic tetracycline use | Swine | Grower-finisher | Farm | Tetracylcine use broken up by treatment group | 1 |
Prophylactic tetracycline use | Swine | Grower-finisher | Farm | Tetracylcine use broken up by treatment group | 1 |
Therapeutic cefpodoxime use | Swine | Grower-finisher | Farm | Cefpodoxime use broken up by treatment group | 1 |
Prophylactic amoxicillin use | Swine | Grower-finisher | Farm | Amoxicillin use broken up by treatment group | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is sul1 gene | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is aadA1 gene | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is dfrA10 gene | 1 |
Prophylactic tiamulin use | Swine | Grower-finisher | Farm | Tiamulin use broken up by treatment group | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is aadA2 gene | 1 |
Therapeutic ceftiofur use | Swine | Grower-finisher | Farm | Ceftiofur use broken up by treatment group | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is tetB gene | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is Int1 gene | 1 |
Prophylactic nitrofurantoin use | Swine | Grower-finisher | Farm | Nitrofurantoin use broken up by treatment group | 1 |
Therapeutic gentamicin use | Swine | Grower-finisher | Farm | Gentamicin use broken up by treatment group | 1 |
Therapeutic cefpirome use | Swine | Grower-finisher | Farm | Cefpirome use broken up by treatment group | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is sul1 gene | 1 |
Prophylactic gentamicin use | Swine | Grower-finisher | Farm | Gentamicin use broken up by treatment group | 1 |
Prophylactic Amoxicillin/clavulanic acid use | Swine | Grower-finisher | Farm | Amoxicillin/clavulanic acid use broken up by treatment group | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is sul2 gene | 1 |
Prophylactic cefpirome use | Swine | Grower-finisher | Farm | Cefpirome use broken up by treatment group | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is aadA1 gene | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is sul3 gene | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is cmlA gene | 1 |
Prophylactic ceftiofur use | Swine | Grower-finisher | Farm | Ceftiofur use broken up by treatment group | 1 |
Therapeutic Amoxicillin/clavulanic acid use | Swine | Grower-finisher | Farm | Amoxicillin/clavulanic acid use broken up by treatment group | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is tetA gene | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is aadB gene | 1 |
Therapeutic enrofloxacin use | Swine | Grower-finisher | Farm | Enrofloxacin use broken up by treatment group | 1 |
Prophylactic cefalexin use | Swine | Grower-finisher | Farm | Cefalexin use broken up by treatment group | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is dfrA1 gene | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is dfrA1 gene | 1 |
Prophylactic piperacillin use | Swine | Grower-finisher | Farm | Piperacillin use broken up by treatment group | 1 |
Therapeutic amoxicillin use | Swine | Grower-finisher | Farm | Amoxicillin use broken up by treatment group | 1 |
Prophylactic amikacin use | Swine | Grower-finisher | Farm | Amikacin use broken up by treatment group | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is blaCTX-M-1 gene | 1 |
Therapeutic imipenem use | Swine | Grower-finisher | Farm | Imipenem use broken up by treatment group | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is catB gene | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is dfrA10 gene | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is cmlA gene | 1 |
Prophylactic Trimethoprim/sulfamethoxazole use | Swine | Grower-finisher | Farm | Trimethoprim/sulfamethoxazole use broken up by treatment group | 1 |
Therapeutic tobramycin use | Swine | Grower-finisher | Farm | Tobramycin use broken up by treatment group | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is blaCTX-M9 gene | 1 |
Therapeutic cefalexin use | Swine | Grower-finisher | Farm | Cefalexin use broken up by treatment group | 1 |
Therapeutic nitrofurantoin use | Swine | Grower-finisher | Farm | Nitrofurantoin use broken up by treatment group | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is tetB gene | 1 |
Prophylactic enrofloxacin use | Swine | Grower-finisher | Farm | Enrofloxacin use broken up by treatment group | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is tetA gene | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is ESBP E. coli gene | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is Int1 gene | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is ESBP E. coli gene | 1 |
Prophylactic AMU | Swine | Grower-finisher | Farm | Resistance outcome is catB gene | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is blaCTX-M-1 gene | 1 |
Prophylactic chloramphenicol use | Swine | Grower-finisher | Farm | Chloramphenicol use broken up by treatment group | 1 |
Therapeutic Trimethoprim/sulfamethoxazole use | Swine | Grower-finisher | Farm | Trimethoprim/sulfamethoxazole use broken up by treatment group | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is sul2 gene | 1 |
Therapeutic marbofloxacin use | Swine | Grower-finisher | Farm | Marbofloxacin use broken up by treatment group | 1 |
Therapeutic AMU | Swine | Grower-finisher | Farm | Resistance outcome is catA gene | 1 |